lundi 18 mars 2019

Onco Actu du 18 mars 2019


1. BIOLOGIE



One experiment: Observing cancer’s progress in a mouse prostate [Cold Spring Harbor lab]











How secret conversations inside cells are transforming biology [Nature]











1.1 BIOLOGIE - GÈNES



Tissue-specificity in cancer: The rule, not the exception [Science]










2. ETIOLOGIE



No, more than 200 scientists did not just sign a petition warning about cancer from Airpods. That doesn’t mean there’s no risk [Quartz]











2.6 ETIOLOGIE - ENVIRONNEMENT



MIT Historian Alleges United Nations Scientific Cover-Up Of Death And Disease Toll From Chernobyl [Forbes]










3.1 PRÉVENTION - TABAC



Stop Smoking Services stubbed out across England [Cancer Research UK]











3.2 PRÉVENTION - OBÉSITÉ



Action needed to stop takeaway temptation harming kids' diets [Cancer Research UK]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Getting at the roots rather than pruning the branches of overdiagnosis [BMJ]










3D printed tungsten could improve gamma camera images [Institute of Cancer Research]











4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...



Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on efforts to evaluate materials in medical devices to address potential safety questions [FDA]










4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Screening service in 'meltdown' as more women attend smears [The Guardian]











4.9 DÉP., DIAG. & PRONO. - SEIN



New Susan G. Komen® Study Unveils High Cost of Diagnostic Tests for Breast Cancer Serves as a Barrier to Needed Care [Komen]











5. TRAITEMENTS



Darolutamide Delays the Spread of Some Prostate Cancers [NCI]











5.10 TRAITEMENTS - ESSAIS



Gottlieb criticizes sponsors’ ‘continued reluctance’ to rethink clinical trials [Fierce Biotech]










FDA's Gottlieb calls for greater adoption of new clinical trial tools [Biopharma Dive]











Scott Gottlieb to biopharma: You wanted us to help modernize R&D, now go out and do it [EndPoints]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China [Fierce Pharma]











5.2 PHARMA



FDA delays Karyopharm PDUFA to review extra information [Fierce Biotech]











Approval decision delay seen as positive for Karyopharm [Biopharma Dive]











Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application [Karyopharm]











5.2.1 PHARMA - PARTENARIATS



ExcepGen emerges from Y Combinator, taking aim at better proteins for drug discovery [Fierce Biotech]











Servier Licenses CureMatch Tech for Custom Cancer Drug Treatments [Xconomy]











Merck KGaA enters drug discovery partnership with AI firm Itkos [Pharmafile]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019 [EMA]











6.11 PATIENTS



'I was diagnosed with cancer at seven months pregnant' [BBC News]











6.4 MÉDICO-ÉCO



Nicola Bennett: The US healthcare system can be a callous and financially menacing force [BMJ]











6.7.1 IA/BIOINFORMATIQUE



TGen Adjusting to New Realities of Bioinformatics for Precision Medicine [Genome Web]











AI Algorithms Are Now Shockingly Good at Doing Science [Wired]